So private institutional investors paying market price ... hhhhm wouldn't they want to have some insights into how the GBM ph3 patients are doing before putting $6.5M into this company? Remember this is an open label trial and 22 patients have been enrolled so far. Results are due in Q3
Market Data 
Markets 
AI
